Summary：**4basebio Strengthens Leadership with Renowned Expert Dr. Jeff Coller's Strategic Advisory Role**CA

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**4basebio Strengthens Leadership with Renowned Expert Dr. Jeff Coller's Strategic Advisory Role**

CAMBRIDGE, UK – June 15, 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, today announces the appointment of Jeff Coller, Ph.D., to its Strategic Advisory Board. Dr. Coller, a distinguished expert in gene therapy and genetic medicines, brings a wealth of knowledge and experience to 4basebio, further bolstering the company's leadership and capabilities in the rapidly evolving genomic medicine landscape.

The appointment of Dr. Coller is a significant development for 4basebio, as it continues to expand its expertise and strengthen its position in the market. With his extensive background in gene therapy and genetic medicines, Dr. Coller will provide strategic guidance to 4basebio, helping the company navigate the complex and rapidly evolving landscape of genomic medicine. His expertise will be invaluable in informing the company's product development and commercialization strategies, as well as its partnerships and collaborations.

The genomic medicine market is experiencing rapid growth, driven by advances in gene editing technologies, synthetic biology, and the increasing demand for innovative treatments for genetic diseases. As the market continues to evolve, companies like 4basebio are well-positioned to capitalize on the opportunities presented by this growth. With Dr. Coller's appointment, 4basebio is strengthening its leadership and capabilities, positioning itself for long-term success in this dynamic and rapidly expanding market.

Looking ahead, 4basebio is poised to leverage Dr. Coller's expertise to drive innovation and growth. The company's focus on synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies is expected to continue, with Dr. Coller's guidance helping to inform its strategic decisions. As the genomic medicine market continues to evolve, 4basebio is well-positioned to remain at the forefront of this exciting and rapidly expanding field.

In conclusion, the appointment of Dr. Jeff Coller to 4basebio's Strategic Advisory Board is a significant development for the company, marking a major milestone in its continued growth and expansion. With Dr. Coller's expertise and guidance, 4basebio is strengthening its leadership and capabilities, positioning itself for long-term success in the rapidly evolving genomic medicine market.